Adverum Biotechnologies (ADVM) Begins New INFINITY Phase 2 Trial for ADVM-022 in Diabetic Macular Edema

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. ABBV
4. META
5. SPY
6. ACN
7. BLZE
8. IBM
9. NKE
10. MU

Go back to Adverum Biotechnologies (ADVM) Begins New INFINITY Phase 2 Trial for ADVM-022 in Diabetic Macular Edema

Adverum Biotechnologies (ADVM) Misses Q1 EPS by 4c

May 28, 2020 4:02 PM EDT

Adverum Biotechnologies (NASDAQ: ADVM) reported Q1 EPS of ($0.31), $0.04 worse than the analyst estimate of ($0.27).

Im thankful for the strong commitment and resilience our employees have exhibited towards advancing our pipeline despite the challenges of COVID 19, said Leone Patterson, president and chief executive officer, Adverum... More